Bearish Downwards Trend. Been shorting since 13.8k after we crossed .61 fib.
Drew that blue line & it seems to be working out perfectly. :D
Buy Target 11k
Sell Target 14.5k
Parabolic run target 16k
Oversold
forexTrdr NZDUSD - TWEEZER BOTTOM BOUNCE FOR KIWIMorning traders
Another start to the week. Monday 17th of June lets go.
Following a very successful short on Gold on Friday from 1354 down to current market at 1333 for our team we are looking for our next winning trade.
Today we are taking a look at a bullish setup on New Zealand dollar versus US dollar following the formation of a Tweezer Bottom candle pattern on the daily chart. What this points to is a reversal of the bearish trend that we had last week. This lines up with RSI being in extreme oversold levels last seen at the end of April and resulted in an 80 pip move higher for the pair.
We are therefore looking for the pair to follow a similar pattern back towards resistance around 0.66 as per our trading view chart where we have highlighted all of the areas of interest.
Good luck trading
from the Team at forexTrdr
find us on instagram, twitter and Alexa flash briefings
KROGER(KR) - Does this make for a good large cap buy?This time we have strong fundamental analysis that supports an upcoming bull run. KR's earnings report came out a couple days ago and were 31.72% greater than expected! However, stronger evidence on the technical side is needed to convince me of a good buy. I'll wait on bullish confirmation from the 12 period EMA and evidence of a turnaround from the MACD.
HEXO close to reversalHEXO GAP down two days ago, now close to be Oversold. Wait for MACD reversal confirmation to buy.
$DVLP is our new 1-cent Cannabis play w/ +800% Revenue Growth &
========================
DVLP (Golden Developing Solutions Inc.)
Alert Price: $0.016
Website | Recent News
Ecommerce: www.puravidavitamins.com
========================
Members,
We're not wasting any time this week.
We've already identified, what is in our opinion one of the biggest steals in the cannabis sector right now.
Please turn your immediate attention to DVLP (Golden Developing Solutions Inc.).
Trading at just over a penny per share, this emerging leader in the Cannabis, Hemp, and CBD marketplace has more upside than most companies operating in the sector.
Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.
DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels.
The Bullish Case for DVLP
Moved into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019. Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
Signed a Letter of Intent (“LOI”) toward the establishment of a licensing agreement to acquire full and exclusive rights to market and distribute a two-time award-winning proprietary line of energy drinks under the DNA Energy Drink® brand designation. The Company intends to market both CBD-infused and non-CBD energy drinks.
Reported Record 800% Jump in Combined-Entity Revenues for March 2019.
Obtained fully-audited fully-reporting status with the SEC following the filing of audited financial data along with Form 10. In addition, the Company is in the process of uplisting shares from the Pink Sheets onto the OTCQB “Venture Market” tier.
Up-listing to the OTCQB should be good for price, liquidity, and potential appreciation of DVLP.
By moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base, some firms, and funds, as some institutions do not invest in stocks listed on the lower tier exchanges.
DVLP sees +800% Revenue Increase
DVLP recently announced that, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018!
We did the quick math, and if DVLP were to continue this monthly revenue trend, annual revenues would equate to over $7M!
We can't think of any companies generating over $7M per year that are trading at just around 1-cent per share, which leads us to believe that DVLP is one of the most undervalued companies in the cannabis space.
This could be your perfect entry point for DVLP.
DVLP has a history of experiencing significant volatility.
In March DVLP traded as low as 0.0143, subsequently rallying to a high of 0.0269, an upside of more than 88% in just a few weeks.
In early April, we watched shares of DVLP run over +32% from $0.0177 to $0.0235.
Then again in late April, shares of DVLP more than doubled from $0.0142 to over $0.03 in just 3-weeks time.
DVLP is now trading back in the range where we believe its upside potential far outweighs its downside risk.
That being said, we ask that you start your research now, and consider building a position in DVLP tomorrow morning at 9:30AM EST!
About Golden Developing Solutions, Inc.
Golden Developing Solutions (DVLP) is developing an online retail business for cannabidiol (CBD), hemp oil and health/wellness-related products. The Company is also developing a high-capacity, high-quality CBD extraction and production facility. In addition, through the website of its joint venture partner, Pura Vida Vitamins (www.PuraVidaVitamins.com), as well as through wholesale and distribution channels, the Company offers a broad range of high-quality, price-competitive products, including traditional vitamins, supplements, and CBD-based tinctures, vapes and soft gels, among other products. Merchandise also includes hemp and CBD-related products and additional products focusing on health and lifestyle.
Golden Developing Solutions is a development-stage company providing business services and/or products supporting the cannabis industry, in which company intends to make acquisitions in the near future. Currently, 29 states and the District of Columbia have passed laws permitting their citizens to use cannabis for medical and/or recreational purposes. Cannabis has shown encouraging signs as a treatment for various medical conditions and has become increasingly more acceptable to the public and society.
DVLP experienced a remarkable 2018, as the company noted in this announcement:
“Golden Developing Solutions Announces Nationwide Expansion of 'Where's Weed' Following Record Breaking $18 Million in Transactions”
A little about this platform:
“Since 2011, Where’s Weed has been dedicated to helping medical and recreational consumers find dispensaries, delivery services, strains, and deals in their local cannabis community.”
“Additionally, the platform helps cannabis companies connect with consumers and more efficiently manage and market their business in the digital space.”
Furthermore, the company announced:
“Golden Developing Solutions Announces 149% Q4 Rev Growth in “Where’s Weed” Division, Sees Accelerating Platform Growth in Q1 and 2019”
DVLP Acquires CBD Infusionz
DVLP secured powerful traction in the cannabis space as a service provider with their popular Where’s Weed app and portal. And, recently, they expanded this market coverage footprint by moving into the CBD space full force with their Where’s CBD portal, which is beginning to take root as a powerful resource.
That sets the stage for what they feel could be a true gamechanger in the quarters ahead, in terms of synergies and overall augmentation of their core growth proposition: their recent acquisition of Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high quality CBD products.
Why do they believe this acquisition is such an important move?
First off, it will immediately augment their topline growth data, which is a core factor for institutional investors in search of strong growth potential. They can now offer a better argument given the strong revenues they assume as we onboard CBD Infusionz. For example, if they backdate our analysis, the combined entity would have had total sales of more than $500K in February alone.
In addition, following this acquisition, they have a fully developed retail, wholesale, distribution, and white labeling operation in the CBD space to augment their Where’s CBD services offering.
In fact, with CBD Infusionz operationally integrated, they will now have on offer more than 150 product SKU’s, including vegan products, pet products, pre-rolls, concentrates, creams and lotions, muscle freeze, massage oil, and premium products with existing brand traction such as the Saucy Boss Concentrate line and the Terpy J Pre-roll line.
In short, they emerge from this deal with a powerful value proposition for new investment capital. Their equity is now trading at just 2X our 2019 projected sales, which represents a run rate of $6 million on an annualized basis at current levels. That run rate is also a fixed point on a steep growth curve that shows evidence of a 4-6 month doubling rate at present.
And, perhaps most importantly, they are tethered to arguably the two most robust growth markets on the planet right now in cannabis and CBD. Following this acquisition, they are now more focused on CBD than we have been in the past because the growth curve is even more robust in CBD than it is in cannabis, given the lack of legal barriers to mainstream adoption by consumers in North America. Recent updated forecasts now anticipate a twenty-fold ramp in total sales volume over the next 36 months in the CBD marketplace to over $20 billion, according to several prominent forecasts.
In other words, we believe, with their recent acquisition of CBD Infusionz, they have assembled the pieces of a very strong shareholder value proposition over coming quarters and years.
They will continue to act according to the principles that have taken them this far. They have a number of exciting plans in the works, and they will do their best to keep you updated as they move forward.
Recent Developments
DVLP Announces Move-In Date for New Denver CBD Production Facility
DENVER, June 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is pleased to announce that the Company will be officially moving into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019.
Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
As noted in the Company’s release dated May 20, 2019, the new facility will house primary production for the Company’s wholly-owned subsidiary, Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high-quality CBD products addressing a wide spectrum of market product niches in the CBD space.
“We are excited to get into the new facility, get organized, and ramp up operations,” commented DVLP CEO Stavros Triant. “This is a massive expansion of our overall production footprint, and we anticipate a correspondingly massive expansion in our growth rate and the value proposition we offer our shareholders. That represents a very strong position for the Company, particularly following passage of Colorado House Bill 1090 last month.”
The Company was excited to receive news of recent bills signed into law by Colorado Governor Jared Polis on May 29, following passage by state legislators in session. House Bill 1090 has particularly strong implications for investments in the Colorado Hemp, Cannabis, and CBD sector, as outlined in a recent piece in the Denver Business Journal. Specifically, the bill allows publicly traded companies to have cannabis licenses and enables more investments in the state’s cannabis industry by venture capitalists and other private equity firms by removing the limit of 15 out-of-state owners per cannabis company.
Mr. Triant continued, “When we acquired CBD Infusionz, the problem they were facing was too much demand and an inability to handle the pace of expansion. That’s the best problem to have in business when you have access to capital and an experienced management team. Colorado is extremely friendly to that mission. The next three months should be the start of a very fun ride.”
Golden Developing Solutions Reports Record 800% Jump in Combined-Entity Revenues for March 2019
DENVER, April 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is excited to announce, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018.
“We are seeing tremendous validation on a strategic level,” commented DVLP CEO Stavros Triant. “The move to expand our exposure to the CBD space was very well-timed, and is already beginning to pay off. The numbers for March bear that out unmistakably.”
Management notes that this data demonstrate a dramatic growth curve on both an annual and sequential monthly basis, with the comparative March monthly year-over-year and the sequential monthly data showing appreciable growth. As noted above, the year-over-year monthly comparable revenue data increased by 800% while the sequential monthly data showed an increase of nearly 18%, which represents a follow-on annualized growth rate of 630% over the coming 12 months.
According to recent macro analysis of the CBD space, that level of growth is not particularly remarkable given the market context. Analysts have begun to project similar exponential growth in the CBD space over the next 36 months following the signing of the 2018 Farm Bill, which opened the door to a much easier path of mainstream expansion in hemp-based CBD sales in the United States.
“As we integrate CBD Infusionz, we will be dramatically increasing our operational potential,” continued Mr. Triant. “Where’s Weed and Where’s CBD have provided powerful growth catalysts on the services side. But the addition of a true leadership asset on the CBD product side sharply amplifies our growth proposition at an ideal time from an industry standpoint.”
Market Outlook:
Growth of “consumer spending on legal cannabis” is expected to “accelerate in 2019, jumping 38% to $16.9 billion."
This number is expected “to reach $31.3 billion in 2022”.
But the US could provide the sector with an even bigger opportunity.
According to Business Insider, “recreational marijuana is now legal in 10 states; medical marijuana is legal in 33.”
But here is where this gets exciting for the sector, and why there has been so much enthusiasm recently…
According to MarketWatch, members of the US Congress plan to pass a Marijuana Banking Bill in 2019.
This could be another positive catalyst for the sector in the US as regulations further ease.
The movement is gaining traction too…
The “New Marijuana Banking Bill In Congress Has 108 Cosponsors”.
In fact, in a huge development, two weeks ago it was reported by Forbes: “Marijuana Banking Bill Approved By Congressional Committee”
This could be another massively positive catalyst for companies in this sector in the world’s largest economy.
Technical Analysis
As we mentioned above, DVLP has historic volatility, and has reversed hard off these levels time and time again.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.16 from today's alert price would net traders over +775% in pure profit!
The Bottom Line
With an +800% revenue increase, and a solid plan for growth, DVLP appears to be grossly undervalued at its current share price.
DVLP has reversed from these levels time and time again.
Those who grab up shares at today's alert price could be handsomely rewarded in the immediate future.
That being said, we ask that all members start their research on DVLP immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP. We have previously been compensated ten thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$DVLP is our new 1-cent Cannabis play w/ +800% Revenue Growth &=====================================
DVLP (Golden Developing Solutions Inc.)
Alert Price: $0.016
Website | Recent News
Ecommerce: www.puravidavitamins.com
======================================
Members,
We're not wasting any time this week.
We've already identified, what is in our opinion one of the biggest steals in the cannabis sector right now.
Please turn your immediate attention to DVLP (Golden Developing Solutions Inc.).
Trading at just over a penny per share, this emerging leader in the Cannabis, Hemp, and CBD marketplace has more upside than most companies operating in the sector.
Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.
DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels.
The Bullish Case for DVLP
Moved into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019. Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
Signed a Letter of Intent (“LOI”) toward the establishment of a licensing agreement to acquire full and exclusive rights to market and distribute a two-time award-winning proprietary line of energy drinks under the DNA Energy Drink® brand designation. The Company intends to market both CBD-infused and non-CBD energy drinks.
Reported Record 800% Jump in Combined-Entity Revenues for March 2019.
Obtained fully-audited fully-reporting status with the SEC following the filing of audited financial data along with Form 10. In addition, the Company is in the process of uplisting shares from the Pink Sheets onto the OTCQB “Venture Market” tier.
Up-listing to the OTCQB should be good for price, liquidity, and potential appreciation of DVLP.
By moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base, some firms, and funds, as some institutions do not invest in stocks listed on the lower tier exchanges.
DVLP sees +800% Revenue Increase
DVLP recently announced that, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018!
We did the quick math, and if DVLP were to continue this monthly revenue trend, annual revenues would equate to over $7M!
We can't think of any companies generating over $7M per year that are trading at just around 1-cent per share, which leads us to believe that DVLP is one of the most undervalued companies in the cannabis space.
This could be your perfect entry point for DVLP.
DVLP has a history of experiencing significant volatility.
In March DVLP traded as low as 0.0143, subsequently rallying to a high of 0.0269, an upside of more than 88% in just a few weeks.
In early April, we watched shares of DVLP run over +32% from $0.0177 to $0.0235.
Then again in late April, shares of DVLP more than doubled from $0.0142 to over $0.03 in just 3-weeks time.
DVLP is now trading back in the range where we believe its upside potential far outweighs its downside risk.
That being said, we ask that you start your research now, and consider building a position in DVLP tomorrow morning at 9:30AM EST!
About Golden Developing Solutions, Inc.
Golden Developing Solutions (DVLP) is developing an online retail business for cannabidiol (CBD), hemp oil and health/wellness-related products. The Company is also developing a high-capacity, high-quality CBD extraction and production facility. In addition, through the website of its joint venture partner, Pura Vida Vitamins (www.PuraVidaVitamins.com), as well as through wholesale and distribution channels, the Company offers a broad range of high-quality, price-competitive products, including traditional vitamins, supplements, and CBD-based tinctures, vapes and soft gels, among other products. Merchandise also includes hemp and CBD-related products and additional products focusing on health and lifestyle.
Golden Developing Solutions is a development-stage company providing business services and/or products supporting the cannabis industry, in which company intends to make acquisitions in the near future. Currently, 29 states and the District of Columbia have passed laws permitting their citizens to use cannabis for medical and/or recreational purposes. Cannabis has shown encouraging signs as a treatment for various medical conditions and has become increasingly more acceptable to the public and society.
DVLP experienced a remarkable 2018, as the company noted in this announcement:
“Golden Developing Solutions Announces Nationwide Expansion of 'Where's Weed' Following Record Breaking $18 Million in Transactions”
A little about this platform:
“Since 2011, Where’s Weed has been dedicated to helping medical and recreational consumers find dispensaries, delivery services, strains, and deals in their local cannabis community.”
“Additionally, the platform helps cannabis companies connect with consumers and more efficiently manage and market their business in the digital space.”
Furthermore, the company announced:
“Golden Developing Solutions Announces 149% Q4 Rev Growth in “Where’s Weed” Division, Sees Accelerating Platform Growth in Q1 and 2019”
DVLP Acquires CBD Infusionz
DVLP secured powerful traction in the cannabis space as a service provider with their popular Where’s Weed app and portal. And, recently, they expanded this market coverage footprint by moving into the CBD space full force with their Where’s CBD portal, which is beginning to take root as a powerful resource.
That sets the stage for what they feel could be a true gamechanger in the quarters ahead, in terms of synergies and overall augmentation of their core growth proposition: their recent acquisition of Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high quality CBD products.
Why do they believe this acquisition is such an important move?
First off, it will immediately augment their topline growth data, which is a core factor for institutional investors in search of strong growth potential. They can now offer a better argument given the strong revenues they assume as we onboard CBD Infusionz. For example, if they backdate our analysis, the combined entity would have had total sales of more than $500K in February alone.
In addition, following this acquisition, they have a fully developed retail, wholesale, distribution, and white labeling operation in the CBD space to augment their Where’s CBD services offering.
In fact, with CBD Infusionz operationally integrated, they will now have on offer more than 150 product SKU’s, including vegan products, pet products, pre-rolls, concentrates, creams and lotions, muscle freeze, massage oil, and premium products with existing brand traction such as the Saucy Boss Concentrate line and the Terpy J Pre-roll line.
In short, they emerge from this deal with a powerful value proposition for new investment capital. Their equity is now trading at just 2X our 2019 projected sales, which represents a run rate of $6 million on an annualized basis at current levels. That run rate is also a fixed point on a steep growth curve that shows evidence of a 4-6 month doubling rate at present.
And, perhaps most importantly, they are tethered to arguably the two most robust growth markets on the planet right now in cannabis and CBD. Following this acquisition, they are now more focused on CBD than we have been in the past because the growth curve is even more robust in CBD than it is in cannabis, given the lack of legal barriers to mainstream adoption by consumers in North America. Recent updated forecasts now anticipate a twenty-fold ramp in total sales volume over the next 36 months in the CBD marketplace to over $20 billion, according to several prominent forecasts.
In other words, we believe, with their recent acquisition of CBD Infusionz, they have assembled the pieces of a very strong shareholder value proposition over coming quarters and years.
They will continue to act according to the principles that have taken them this far. They have a number of exciting plans in the works, and they will do their best to keep you updated as they move forward.
Recent Developments
DVLP Announces Move-In Date for New Denver CBD Production Facility
DENVER, June 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is pleased to announce that the Company will be officially moving into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019.
Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
As noted in the Company’s release dated May 20, 2019, the new facility will house primary production for the Company’s wholly-owned subsidiary, Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high-quality CBD products addressing a wide spectrum of market product niches in the CBD space.
“We are excited to get into the new facility, get organized, and ramp up operations,” commented DVLP CEO Stavros Triant. “This is a massive expansion of our overall production footprint, and we anticipate a correspondingly massive expansion in our growth rate and the value proposition we offer our shareholders. That represents a very strong position for the Company, particularly following passage of Colorado House Bill 1090 last month.”
The Company was excited to receive news of recent bills signed into law by Colorado Governor Jared Polis on May 29, following passage by state legislators in session. House Bill 1090 has particularly strong implications for investments in the Colorado Hemp, Cannabis, and CBD sector, as outlined in a recent piece in the Denver Business Journal. Specifically, the bill allows publicly traded companies to have cannabis licenses and enables more investments in the state’s cannabis industry by venture capitalists and other private equity firms by removing the limit of 15 out-of-state owners per cannabis company.
Mr. Triant continued, “When we acquired CBD Infusionz, the problem they were facing was too much demand and an inability to handle the pace of expansion. That’s the best problem to have in business when you have access to capital and an experienced management team. Colorado is extremely friendly to that mission. The next three months should be the start of a very fun ride.”
Golden Developing Solutions Reports Record 800% Jump in Combined-Entity Revenues for March 2019
DENVER, April 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is excited to announce, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018.
“We are seeing tremendous validation on a strategic level,” commented DVLP CEO Stavros Triant. “The move to expand our exposure to the CBD space was very well-timed, and is already beginning to pay off. The numbers for March bear that out unmistakably.”
Management notes that this data demonstrate a dramatic growth curve on both an annual and sequential monthly basis, with the comparative March monthly year-over-year and the sequential monthly data showing appreciable growth. As noted above, the year-over-year monthly comparable revenue data increased by 800% while the sequential monthly data showed an increase of nearly 18%, which represents a follow-on annualized growth rate of 630% over the coming 12 months.
According to recent macro analysis of the CBD space, that level of growth is not particularly remarkable given the market context. Analysts have begun to project similar exponential growth in the CBD space over the next 36 months following the signing of the 2018 Farm Bill, which opened the door to a much easier path of mainstream expansion in hemp-based CBD sales in the United States.
“As we integrate CBD Infusionz, we will be dramatically increasing our operational potential,” continued Mr. Triant. “Where’s Weed and Where’s CBD have provided powerful growth catalysts on the services side. But the addition of a true leadership asset on the CBD product side sharply amplifies our growth proposition at an ideal time from an industry standpoint.”
Market Outlook:
Growth of “consumer spending on legal cannabis” is expected to “accelerate in 2019, jumping 38% to $16.9 billion."
This number is expected “to reach $31.3 billion in 2022”.
But the US could provide the sector with an even bigger opportunity.
According to Business Insider, “recreational marijuana is now legal in 10 states; medical marijuana is legal in 33.”
But here is where this gets exciting for the sector, and why there has been so much enthusiasm recently…
According to MarketWatch, members of the US Congress plan to pass a Marijuana Banking Bill in 2019.
This could be another positive catalyst for the sector in the US as regulations further ease.
The movement is gaining traction too…
The “New Marijuana Banking Bill In Congress Has 108 Cosponsors”.
In fact, in a huge development, two weeks ago it was reported by Forbes: “Marijuana Banking Bill Approved By Congressional Committee”
This could be another massively positive catalyst for companies in this sector in the world’s largest economy.
Technical Analysis
As we mentioned above, DVLP has historic volatility, and has reversed hard off these levels time and time again.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.16 from today's alert price would net traders over +775% in pure profit!
The Bottom Line
With an +800% revenue increase, and a solid plan for growth, DVLP appears to be grossly undervalued at its current share price.
DVLP has reversed from these levels time and time again.
Those who grab up shares at today's alert price could be handsomely rewarded in the immediate future.
That being said, we ask that all members start their research on DVLP immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP. We have previously been compensated ten thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Trade setup: EUR/AUD analysisideally, the price could tap the -27% retracement zone or spike above to the key minor resistance before reversing
Overbought overreaction: short BYND 138c June 14BYND reported earnings with a wider loss in the first quarter of 2019 due to higher costs and expenses, but outstanding guidance for next year. Even bullish analysts have set price targets below the current market price of $135. JPMorgan is overweight with a $120 price target, Bernstein rates outperform with a $107 price target, Credit Suisse sets a price target of $125, Goldman set a target of $76 and BoA Merrill Lynch sets a price target of $101. Competition is also increasing in the already-crowded space. Nestle announced earlier this week that they will launch a plant-based burger, dubbed "the Awesome Burger." Burger King in in the process of adding the Impossible Foods burger nationwide and Tyson Foods is creating a plant-based protein that is mirrors Beyond's offerings.
Beyond Meat is only one brand in a very competitive space. This huge jump of over 35% after reporting more losses, yet a "positive outlook" despite increasing vehement competition is an overreaction. The RSI indicators show a reading of a whopping 81, indicating that BYND stock is extremely overbought. BYND is also trading outside of the bollingers, making it fit for mean reversion. The MACD indicator also shows that the momentum is waning. The Parabolic Stop and Reverse indicator is now above the candles, indicating a bearish movement to come. We are thus shorting the 138 calls with June 14th expiry (next Friday). This benefits from the expensive contract prices because of high implied volatility, and the near-term expiry thus allows us to collect theta premium.
HOTH delivers +13% in profits so far & could jump past $8 today!=====================
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Current Price: $6.80
Low: $6.75
High: $7.90
Realistic Gains/Loss: +13.18%
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
Yesterday's low-float Nasdaq listed alert HOTH (Hoth Therapeutics, Inc.) started the day off hot, delivering up +13.18% in realistic profit.
It then appeared that some profit taking took place, and shares pulled back to their day low of $6.70.
HOTH appeared to form a base at those levels and bounced back in the afternoon, nearly closing in the green on heavy volume.
We are banking that this afternoon's momentum will continue on into tomorrow's session.
Especially considering the fact that we don't believe the Street got the full effect of yesterday's news release.
This morning HOTH dropped huge news regarding its positive steps towards getting FDA approval for their game changing treatment for eczema, BioFlexa.
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution
NEW YORK, June 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced the formation of its subsidiary, Hoth Therapeutics Australia Pty Ltd, in anticipation to perform clinical trials for atopic dermatitis.
Hoth Therapeutics Australia Pty Ltd will oversee the preparation and execution of Hoth's first clinical trial, known as Efficacy and Safety of BioLexa for the Treatment of Mild-to-Moderate Atopic Dermatitis. The newly formed entity will also be eligible for a significant Research and Development tax rebate. The subsidiary will supervise data management, biostatistical, medical monitoring, quality insurance, regulatory and central laboratory services to support the trial.
"We are excited by the opportunity to work with Australian researchers and members of the international pharmaceutical industry, in regards to the development of our proprietary atopic dermatitis treatment," stated Mr. Robb Knie, CEO of Hoth Therapeutics. "This endeavor is a significant milestone for us, as we move towards clinical trials. Hoth is committed to working diligently with physicians, and regulators in order to successfully pilot our BioLexa Platform to the millions of people that are afflicted with atopic dermatitis."
The subsidiary was formed in connection with Novotech and CoSec Consulting. Headquartered in Australia since 1996 and operating in the Asia Pacific region, Novotech is internationally recognized in the industry as a leading regional full-service contract research organization. Cosec Consulting provides carefully crafted compliance, governance and financial solutions for offshore companies undertaking research and development activities in Australia.
This market friendly news sent shares soaring this morning, but we can only imagine the type of move it will make once it has more eyes on it.
We also noticed that the Level II on this low-float biotech play is extremely thin, and we are anticipating a possible move past $8.00 when all is said and done.
We witnessed some wild swings between $6 and $7 yesterday, with a little more volume HOTH could easily run past $8.
Remember...
HOTH is the perfect candidate for a monster breakout.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
On Wednesday we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
This is the only ticker that should be on your radar today.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Click here to view our full profile on HOTH.
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
USDCAD - Entering BUY Zone USDCAD has been trading between a channel for over 2 years.
This provides opportunity to buy from 1.3320
My stop loss will be set below 1.3250
Good luck!
Add ANFI to the top of your watchlist. SIgns $6M Contract +
=====================
ANFI (Amira Nature Foods Ltd.)
Float: 25.82M
Alert Price: $1.05
Target Price: $6.00
Chart Analysis
Investor Presentation
Investor Webcast
Website | Recent News
========================
Members,
Our biggest NYSE-listed winner of 2019 looks ready to breakout big once again!
It's time to add ANFI (Amira Nature Foods Ltd.) back to the top of your watchlist.
After pulling back substantially from its 52-week high, ANFI appears to have found its bottom.
The Company has recently made some market friendly announcements that we believe will serve as huge catalysts for an epic chart reversal.
Announced the hiring of Brian M. Speck as Chief Financial Officer. With his many years of U.S. public company accounting experience Mr. Speck will assist ANFI in Westernizing their finance department as they focus on the international growth of their brands.
Entered into contracts, which consist of approximately $9 million in revenue, to supply rice and institutional products to new customers in the Europe, Middle East, and Africa (“EMEA”) and Asia regions. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020. “We are extremely pleased to announce this order, which along with our previously announced customer order of $42M, amounts to over $51M. This equates to securing 26% of our forecasted $200M of FY2020 revenue just 52 days (14%) into the fiscal year”, stated Karan A. Chanana, Amira’s Chairman.
ANFI's recent strategic moves have us extremely bullish on this past triple-digit winner.
In fact, we've done our very own chart analysis and see the potential for a move of over +153% in the very near future!
If you've been following our recent alerts, you should know that our price targets have been pretty much right on the money.
But that price target is quite modest compared to what Wall Street analysts are betting on.
Top 10 Wealth Firm Puts $6.00 Price Target on a $1.00 Stock
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
That's an upside of +471% from today's alert price!
If you go to Google and search for the "Top 10 Wealth Firms" you'll notice that " Jefferies Wealth Management" is in the top 10 in the country.
If that wasn't enough to have you sold on ANFI, you'll be happy to know that Jefferies isn't the only equity research firm that is bullish on ANFI...
Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies recently initiated coverage on ANFI, and slapped on a $4.00 price target!
That's well over +280% in upside potential from today's alert price.
Their full research report is available here.
To say that ANFI is undervalued at its current share price would be the understatement of the year.
Here are a few other reasons why we have an extremely bullish outlook ANFI:
Low float of just 25.82M
Listed on the NYSE (High Liquidity)
Products now available on Amazon in the United Kingdom. The Company is initially offering its Brown Basmati Rice 2kg product and is looking forward to adding more products.
Reiterated its $200 million revenue guidance for the 2020 fiscal year ending March 31, 2020. Going forward, the Company’s focus will be on strengthening its international business and as such the 2020 fiscal year $200 million revenue guidance consists solely of international revenue (ex-India).
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
Trading well below its average analyst price target of $6.00 (+471% Upside)
Its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
It's Indian subsidiary, Amira Foods India (“Amira India”), has converted Amira India debt into ordinary shares of Amira India. As a result of the debt conversion, the Company’s ownership in Amira India decreased from 80.4% to 49.8%. This event is a continuation of Amira’s focus on strengthening the Company’s international business.
It is our opinion that ANFI is shaping up to be one of the top growth/value plays listed on the NYSE at the moment.
As such, we ask that all members start their research on ANFI immediately, and consider building a position this morning at 9:30AM EST
About Amira Nature Foods
Founded in 1915, Amira has evolved into a global provider of packaged Indian specialty rice, with sales in over 40 countries today. Amira sells Basmati rice, premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. Amira sells its products primarily in emerging markets through a broad distribution network. Amira’s headquarters are in Dubai, United Arab Emirates, and it also has offices in India, Germany, the United Kingdom, and the United States.
Company Highlights:
Large Staple Consumer Category with Highly Supportive Industry and Sub Category Fundamentals
A Market Lead with Differentiated Business Model
Globally Diversified with Wide Customer Base and Broad Product Portfolio
Vertically Integrated "State-of-the-art" Supply Chain and Operations
Strong Financial Track Record, Underpinned by Stable Margins
Highly Experienced and Successful Management Team
Announced that its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
Since its founding in 1915, Amira has evolved from a domestic, family owned Indian business to a professionally managed, global branded, publicly traded, growing packaged food company.
Not only is the stock potentially undervalued based on its revenues and earnings, ANFI is also trading well below its book value, with a price-to-book ratio of 0.10, while the industry average is 1.81.
With ANFI trading well below the industry average for some key valuation ratios, it could be a value play, and could even attract potential buyers.
Moreover, Amira was able to increase at a compound annual growth rate of 15.5% between 2010 and 2017. With such high revenue growth rates, this company could be significantly undervalued by the market.
According to Finviz, over 50% of the company is owned by insiders. That in mind, that shows that the company’s officers, directors, and key insiders are confident in the company.
The Company has received numerous accolades:
Since 2010, Amira has been recognized in multiple years by the World Economic Forum as a “Global Growth Company”, an
invitation-only community consisting of ~300 of the world’s fastest-growing corporations
The World Consulting & Research Corporation named Amira one of “Asia’s Most Promising Brands”
Planman Marcom voted Amira the “INDIAN POWERBRAND” in the Food Category in 2011 and 2013
Amir was voted best partner in the “Staples” category in 2013 at the Bharti Walmart Private Limited Annual Supplier Conference
VWP World Brand recognized the Amira Brand as “The Admired Brand of India” in 2014–2015
Inc. India featured Amira as one of India’s fastest growing mid-sized companies in 2010, 2011, 2012 and 2013
Product Portfolio
Approximately three quarters of sales come from Basmati rice, the core focus of the company;
Sells more than 20 owned brands globally, spanning numerous price points;
Amira in India
Amira has established 15 Company managed distribution centers in India to provide it greater control over its expansion efforts in its home country location.
Amira is one of a handful of large relevant players in the domestic India market.
Amira represents a meaningful opportunity to consolidate the market over time.
Business Is Growing, Strategic Moves Will Expedite Growth
Amira Foods is no startup. The international business is healthy and generated roughly $270 million in sales in 2018. Those numbers are coupled with respectable margins that rested at 14.3% of gross sales. However, the company expects to do better with the expectation to add an additional 100bp to the international margins. Notably, there will some be shrinkage to the margins, which may be adjusted lower to account for the separation of the Indian business, due to less vertical integration and less sourcing from the primary processor. However, even with the expected reductions in the margin and certain efficiencies, analysts are pointing to ANFI being able to maintain separate sales of roughly $200 million, albeit with a lower margin of approximately 650bp. However, even with the expected short-term declines, the assumption of the lesser $200 million in sales coupled with an EBITDA margin of an expected 8.8%, can imply that ANFI will generate a positive EBITDA run of roughly $17 million. And, that is a healthy number to build upon.
Source: seekingalpha.com
Recent Developments
Appointment of Thomas Dennhardt (formerly Lidl) to CEO of Amira Basmati Rice GmbH (German subsidiary)
Board appointment of Hervé Larren (formerly LVMH), bringing experience in building brands internationally
EUR25mn Debt raise at 8.5% interest rate (due December 2023)
Reduced ownership of India subsidiary to 49.8%
Regains Compliance with NYSE Listing Requirements
Latest News
Amira Nature Foods Ltd Hires Brian M. Speck as Chief Financial Officer
Amira Nature Foods Ltd (the "Company") (ANFI), a global provider of packaged specialty rice, today announced the hiring of Brian M. Speck as Chief Financial Officer. The Company continues to focus on the international growth of its brands and as such, continues to take steps to Westernize its corporate finance and executive team.
Karan A. Chanana, Amira’s Chairman, commented, “Brian Speck is an excellent addition to our team, bringing his extensive financial and consumer industry background to the Company. We believe his many years of U.S. public company accounting experience will assist Amira in Westernizing our finance department as we focus on the international growth of our brands.”
“I am excited to join the Company at a pivotal time in its history and helping it realize its international growth strategy,” Mr. Speck said. “After spending nearly two decades in various accounting roles, I look forward to bringing my experience to assist Amira’s efforts to grow its brands outside of India.”
Since March 2018, Mr. Speck has been the Chief Financial Officer of Surge Holdings, Inc., a provider of a suite of financial and telecommunications services which are primarily marketed through small retail establishments which are utilized by members of its target market. Since October 2013, Mr. Speck has also been Director of Financial Reporting for Brio Financial Group, which the Company recently announced would be assisting the Company in its ongoing financial reporting. In his capacity at Brio, Mr. Speck consults various private and public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, from 2011 to 2013, he was an audit supervisor at Wiss & Company. In that capacity, he was involved in the firm’s accounting and tax practice with industry focuses in manufacturing, wholesalers, construction contractors and professional service firms. Mr. Speck received a Master of Science in Accounting from Kean University.
Market Outlook:
Amira operates in the global packaged rice market and is a leading provider of Basmati rice, a long-grain aromatic rice with favorable health attributes that can be grown only in specific regions of the Indian sub-continent and part of the Punjab region located in Pakistan. The global rice market is an enormous market with stable growth, while specialty rice and specifically Basmati rice benefits from premium pricing and increasing consumption patterns. Demand for Basmati rice has remained strong over the past 10 years due to the increased consumption trends both in India and internationally. Leading players such as McCormick & Co., Hain Celestial, Rice 'n Spice, LT Foods, East End Foods, and Amira Nature Foods serve local as well as global consumers, which is reflected in the growth of Basmati rice market. The size of worldwide Basmati rice market was approximately $10.51 Billion in 2017 and is estimated to be worth $17.74 Billion by the end of 2022, with a robust CAGR of 11% between 2017 and 2022, according to Transparency Market Research (TMR).
Rice is a $275bn Global Staple Category with Favorable Market Conditions
Rice is the primary staple for >50% of the world’s population and provides > 20% of the global caloric intake
Represents 30% of caloric consumption in Asia(4)
Defensive and non-cyclical with steady growth
Improves with age and has an extremely long shelf life (up to 5+ years) if stored properly
Global rice consumption is growing, estimated to reach c.483 million metric tonnes in 2017(5)
The global rice market is estimated at $275B and has grown at 2% volume CAGR over the 2010 – 2015 period
Technical Analysis
As we stated above, we've done our very own chart analysis and see the potential for a move of over +153% from here!
We see a positive reversal from long-term support right here, and a positive cross looks imminent.
The float of ANFI is extremely low for a NYSE listed company at just 25.82M.
We know this ticker can make big moves on volume, so we wouldn't be too surprised if this ticker starts to breakout early.
With its bullish $6.00 price target, we believe its upside potential far outweighs any downside risk.
The Bottom Line
ANFI has proven its ability run-up big in both the short and long-term.
ANFI has the potential to be the biggest gainer on the NYSE, and deserves to be on the top of your watchlist.
That being said, we ask that all members start their research on ANFI immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI. We have previously been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI on three separate occasions which have expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Add $ANFI to the top of your watchlist. SIgns $6M Contract + =====================
ANFI (Amira Nature Foods Ltd.)
Float: 25.82M
Alert Price: $1.05
Target Price: $6.00
Chart Analysis
Investor Presentation
Investor Webcast
Website | Recent News
========================
Members,
Our biggest NYSE-listed winner of 2019 looks ready to breakout big once again!
It's time to add ANFI (Amira Nature Foods Ltd.) back to the top of your watchlist.
After pulling back substantially from its 52-week high, ANFI appears to have found its bottom.
The Company has recently made some market friendly announcements that we believe will serve as huge catalysts for an epic chart reversal.
Announced the hiring of Brian M. Speck as Chief Financial Officer. With his many years of U.S. public company accounting experience Mr. Speck will assist ANFI in Westernizing their finance department as they focus on the international growth of their brands.
Entered into contracts, which consist of approximately $9 million in revenue, to supply rice and institutional products to new customers in the Europe, Middle East, and Africa (“EMEA”) and Asia regions. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020. “We are extremely pleased to announce this order, which along with our previously announced customer order of $42M, amounts to over $51M. This equates to securing 26% of our forecasted $200M of FY2020 revenue just 52 days (14%) into the fiscal year”, stated Karan A. Chanana, Amira’s Chairman.
ANFI's recent strategic moves have us extremely bullish on this past triple-digit winner.
In fact, we've done our very own chart analysis and see the potential for a move of over +153% in the very near future!
If you've been following our recent alerts, you should know that our price targets have been pretty much right on the money.
But that price target is quite modest compared to what Wall Street analysts are betting on.
Top 10 Wealth Firm Puts $6.00 Price Target on a $1.00 Stock
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
That's an upside of +471% from today's alert price!
If you go to Google and search for the "Top 10 Wealth Firms" you'll notice that " Jefferies Wealth Management" is in the top 10 in the country.
If that wasn't enough to have you sold on ANFI, you'll be happy to know that Jefferies isn't the only equity research firm that is bullish on ANFI...
Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies recently initiated coverage on ANFI, and slapped on a $4.00 price target!
That's well over +280% in upside potential from today's alert price.
Their full research report is available here.
To say that ANFI is undervalued at its current share price would be the understatement of the year.
Here are a few other reasons why we have an extremely bullish outlook ANFI:
Low float of just 25.82M
Listed on the NYSE (High Liquidity)
Products now available on Amazon in the United Kingdom. The Company is initially offering its Brown Basmati Rice 2kg product and is looking forward to adding more products.
Reiterated its $200 million revenue guidance for the 2020 fiscal year ending March 31, 2020. Going forward, the Company’s focus will be on strengthening its international business and as such the 2020 fiscal year $200 million revenue guidance consists solely of international revenue (ex-India).
Jefferies analyst Akshay Jagdale recently maintained his Buy rating on ANFI and set a price target of $6.
Trading well below its average analyst price target of $6.00 (+471% Upside)
Its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
It's Indian subsidiary, Amira Foods India (“Amira India”), has converted Amira India debt into ordinary shares of Amira India. As a result of the debt conversion, the Company’s ownership in Amira India decreased from 80.4% to 49.8%. This event is a continuation of Amira’s focus on strengthening the Company’s international business.
It is our opinion that ANFI is shaping up to be one of the top growth/value plays listed on the NYSE at the moment.
As such, we ask that all members start their research on ANFI immediately, and consider building a position this morning at 9:30AM EST
About Amira Nature Foods
Founded in 1915, Amira has evolved into a global provider of packaged Indian specialty rice, with sales in over 40 countries today. Amira sells Basmati rice, premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. Amira sells its products primarily in emerging markets through a broad distribution network. Amira’s headquarters are in Dubai, United Arab Emirates, and it also has offices in India, Germany, the United Kingdom, and the United States.
Company Highlights:
Large Staple Consumer Category with Highly Supportive Industry and Sub Category Fundamentals
A Market Lead with Differentiated Business Model
Globally Diversified with Wide Customer Base and Broad Product Portfolio
Vertically Integrated "State-of-the-art" Supply Chain and Operations
Strong Financial Track Record, Underpinned by Stable Margins
Highly Experienced and Successful Management Team
Announced that its previously announced $30 million contract to supply third party branded basmati rice to a repeat customer in the Europe, Middle East, and Africa (“EMEA”) region was increased to $42 million within the provisions of the contract. The Company expects to recognize the benefit of this contract in the 2020 fiscal year ending March 31, 2020.
Since its founding in 1915, Amira has evolved from a domestic, family owned Indian business to a professionally managed, global branded, publicly traded, growing packaged food company.
Not only is the stock potentially undervalued based on its revenues and earnings, ANFI is also trading well below its book value, with a price-to-book ratio of 0.10, while the industry average is 1.81.
With ANFI trading well below the industry average for some key valuation ratios, it could be a value play, and could even attract potential buyers.
Moreover, Amira was able to increase at a compound annual growth rate of 15.5% between 2010 and 2017. With such high revenue growth rates, this company could be significantly undervalued by the market.
According to Finviz, over 50% of the company is owned by insiders. That in mind, that shows that the company’s officers, directors, and key insiders are confident in the company.
The Company has received numerous accolades:
Since 2010, Amira has been recognized in multiple years by the World Economic Forum as a “Global Growth Company”, an
invitation-only community consisting of ~300 of the world’s fastest-growing corporations
The World Consulting & Research Corporation named Amira one of “Asia’s Most Promising Brands”
Planman Marcom voted Amira the “INDIAN POWERBRAND” in the Food Category in 2011 and 2013
Amir was voted best partner in the “Staples” category in 2013 at the Bharti Walmart Private Limited Annual Supplier Conference
VWP World Brand recognized the Amira Brand as “The Admired Brand of India” in 2014–2015
Inc. India featured Amira as one of India’s fastest growing mid-sized companies in 2010, 2011, 2012 and 2013
Product Portfolio
Approximately three quarters of sales come from Basmati rice, the core focus of the company;
Sells more than 20 owned brands globally, spanning numerous price points;
Amira in India
Amira has established 15 Company managed distribution centers in India to provide it greater control over its expansion efforts in its home country location.
Amira is one of a handful of large relevant players in the domestic India market.
Amira represents a meaningful opportunity to consolidate the market over time.
Business Is Growing, Strategic Moves Will Expedite Growth
Amira Foods is no startup. The international business is healthy and generated roughly $270 million in sales in 2018. Those numbers are coupled with respectable margins that rested at 14.3% of gross sales. However, the company expects to do better with the expectation to add an additional 100bp to the international margins. Notably, there will some be shrinkage to the margins, which may be adjusted lower to account for the separation of the Indian business, due to less vertical integration and less sourcing from the primary processor. However, even with the expected reductions in the margin and certain efficiencies, analysts are pointing to ANFI being able to maintain separate sales of roughly $200 million, albeit with a lower margin of approximately 650bp. However, even with the expected short-term declines, the assumption of the lesser $200 million in sales coupled with an EBITDA margin of an expected 8.8%, can imply that ANFI will generate a positive EBITDA run of roughly $17 million. And, that is a healthy number to build upon.
Source: seekingalpha.com
Recent Developments
Appointment of Thomas Dennhardt (formerly Lidl) to CEO of Amira Basmati Rice GmbH (German subsidiary)
Board appointment of Hervé Larren (formerly LVMH), bringing experience in building brands internationally
EUR25mn Debt raise at 8.5% interest rate (due December 2023)
Reduced ownership of India subsidiary to 49.8%
Regains Compliance with NYSE Listing Requirements
Latest News
Amira Nature Foods Ltd Hires Brian M. Speck as Chief Financial Officer
Amira Nature Foods Ltd (the "Company") (ANFI), a global provider of packaged specialty rice, today announced the hiring of Brian M. Speck as Chief Financial Officer. The Company continues to focus on the international growth of its brands and as such, continues to take steps to Westernize its corporate finance and executive team.
Karan A. Chanana, Amira’s Chairman, commented, “Brian Speck is an excellent addition to our team, bringing his extensive financial and consumer industry background to the Company. We believe his many years of U.S. public company accounting experience will assist Amira in Westernizing our finance department as we focus on the international growth of our brands.”
“I am excited to join the Company at a pivotal time in its history and helping it realize its international growth strategy,” Mr. Speck said. “After spending nearly two decades in various accounting roles, I look forward to bringing my experience to assist Amira’s efforts to grow its brands outside of India.”
Since March 2018, Mr. Speck has been the Chief Financial Officer of Surge Holdings, Inc., a provider of a suite of financial and telecommunications services which are primarily marketed through small retail establishments which are utilized by members of its target market. Since October 2013, Mr. Speck has also been Director of Financial Reporting for Brio Financial Group, which the Company recently announced would be assisting the Company in its ongoing financial reporting. In his capacity at Brio, Mr. Speck consults various private and public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, from 2011 to 2013, he was an audit supervisor at Wiss & Company. In that capacity, he was involved in the firm’s accounting and tax practice with industry focuses in manufacturing, wholesalers, construction contractors and professional service firms. Mr. Speck received a Master of Science in Accounting from Kean University.
Market Outlook:
Amira operates in the global packaged rice market and is a leading provider of Basmati rice, a long-grain aromatic rice with favorable health attributes that can be grown only in specific regions of the Indian sub-continent and part of the Punjab region located in Pakistan. The global rice market is an enormous market with stable growth, while specialty rice and specifically Basmati rice benefits from premium pricing and increasing consumption patterns. Demand for Basmati rice has remained strong over the past 10 years due to the increased consumption trends both in India and internationally. Leading players such as McCormick & Co., Hain Celestial, Rice 'n Spice, LT Foods, East End Foods, and Amira Nature Foods serve local as well as global consumers, which is reflected in the growth of Basmati rice market. The size of worldwide Basmati rice market was approximately $10.51 Billion in 2017 and is estimated to be worth $17.74 Billion by the end of 2022, with a robust CAGR of 11% between 2017 and 2022, according to Transparency Market Research (TMR).
Rice is a $275bn Global Staple Category with Favorable Market Conditions
Rice is the primary staple for >50% of the world’s population and provides > 20% of the global caloric intake
Represents 30% of caloric consumption in Asia(4)
Defensive and non-cyclical with steady growth
Improves with age and has an extremely long shelf life (up to 5+ years) if stored properly
Global rice consumption is growing, estimated to reach c.483 million metric tonnes in 2017(5)
The global rice market is estimated at $275B and has grown at 2% volume CAGR over the 2010 – 2015 period
Technical Analysis
As we stated above, we've done our very own chart analysis and see the potential for a move of over +153% from here!
We see a positive reversal from long-term support right here, and a positive cross looks imminent.
The float of ANFI is extremely low for a NYSE listed company at just 25.82M.
We know this ticker can make big moves on volume, so we wouldn't be too surprised if this ticker starts to breakout early.
With its bullish $6.00 price target, we believe its upside potential far outweighs any downside risk.
The Bottom Line
ANFI has proven its ability run-up big in both the short and long-term.
ANFI has the potential to be the biggest gainer on the NYSE, and deserves to be on the top of your watchlist.
That being said, we ask that all members start their research on ANFI immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI. We have previously been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources In LLC to conduct investor relations advertising and marketing for ANFI on three separate occasions which have expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Tesla has Strong Technicals to ReverseTesla is approaching strong support that has been present for multiple years. It is also massively oversold and if nothing else, due for a dead cat bounce to retest the downtrend. This looks to be a strong buy with low risk and great for long time investment. Happy Trading!
Please donate if you like what I do! :)
bitcoin: 1NTkRex1gE2iJ63sFQHNpFYkBoeZ3w69FZ
bitcoin-cash: 1GYPijuWfRYtaWmFbPsFjWsozEP3ZXaheq
ethereum: 0x56E49FB49221623C8FC7BE27C49E6d7Ff8d02c70
burstcoin: BURST-S9HQ-84BX-CXX8-4RKBC
I haven't posted in a while but I am really looking into getting back into posting here so if you like what I do, a follow would make my day :)
Using Relative Strength Index in crypto BNBUSDT In this chart I use the RSI (Relative Strength Index), as an indicator of crypto overselling or overbuying. It’s a indicator used in technical analysis.
In general, it helps to establish if the tittle has buying or selling pressure over the trading period. On the charts, trending line is between the upper and lower line. When the trend line cross them, it indicates overselling (lower) or overbought (upper).
Buy EURJPY (4H)in 4H chart:
head and shoulders pattern
61.8% fibo retracement of last bullish wave
Hidden divergence in RSI indicator (Continuous trend)
Oversold in RSI indicator
Support level at 124.8
> Buy
Entry : 124.85
-Stop : 124.15 (70 pips)
-TP1- : 125.95 (110 pips)
-TP2- : 127.30 (245 pips)
GTEH belongs on the top of your watchlist. Only 1.2M in the floa========================
GTEH (GenTech Holdings Inc.)
Alert Price: $0.0331
Float: 1.12M
Chart Analysis
Company Website | Recent News
========================
Members,
Are ready to end this already highly profitable week of trading with a potential triple-digit gainer?
Please turn your immediate attention to GTEH (GenTech Holdings Inc.).
GTEH is in the process of creating a national chain of Hemp Centric Coffee Shop Retail Spaces where patrons can relax, drink CBD infused Teas and Coffees, try various own-brand products and experience holistic education and classes. The company is also building an extensive outreach program working with medical practitioners across the country in their own locations to educate their patients and increase awareness of the benefits of THC free CBD Products.
All of this is offered under the brand 'The Healthy Leaf'.
GTEH plans to enter the Apparel space and then, shortly after, the Consumer Goods sectors of the Hemp industry. Their intention is to continue to build a strong Board that can go into the growing market in the second half of the year with the acquisition of land ready for the growing of Hemp and producing CBD oils and products.
Here's why GTEH needs to be the only ticker on your radar:
Has one of the tightest floats we've ever seen.
Has a well recorded history of monster single-session moves.
Operates in a booming multi-billion dollar cannabis market.
The Company is on a three-year trajectory that will see them launch new branding, make strategic acquisitions and deliver its own branded CBD oil throughout 2019 and into 2021.
Recently announced the establishment of final lease negotiations for its first CBD coffee shop location.
We believe that this highly volatile, low-float alert has the potential to run-up triple-digits tomorrow.
In fact, we've done our very own chart analysis, and see the potential for a move of +282% from today's alert price!
About GenTech Holdings, Inc.
GenTech Holdings, Inc. is a publicly traded company under the symbol GTEH. The company is creating a national chain of Hemp Centric Coffee Shop Retail Spaces where patrons can relax, drink CBD infused Teas and Coffees, try various own-brand products and experience holistic education and classes. The company is also building an extensive outreach program working with medical practitioners across the country in their own locations to educate their patients and increase awareness of the benefits of THC free CBD Products. All of this is offered under the brand 'The Healthy Leaf'.
GTEH recently announced its line of high-end CBD products set to be offered in the launch of its new "The Healthy Leaf" CBD brand over coming weeks.
The initial products to be offered under "The Healthy Leaf" brand will include:
High-End CBD-infused Box of Chocolates
Premium CBD-infused Skin Cream
CBD-infused Artisan Teas
CBD-infused Artisan Coffees
Premium CBD Wellness Snack Bar
High-End CBD-infused Pet Treats
250ml Bottle of Premium CBD
"We are laser-focused on differentiating ourselves from the herd as we launch The Healthy Leaf," commented David Lovatt, CEO of GenTech. "The health and wellness space is a culture. By focusing on a holistic lifestyle branding process, we are lining ourselves up with that culture, and with our target market. Everything flows from that idea."
To assist with the launch, the Company has retained the services of Oxygen Graphics, a premier International Design Company. Oxygen will be tasked with logo design and the creation of the graphic representations that will define the brand, including business cards, kiosk and delivery truck insignias, product packaging design and graphics, labels, and web graphics.
In addition, as part of the primary launch, the Company will be launching its new web presence in the form of a sophisticated customer-facing website, which will include an e-commerce engine preview and a 3D walk-thru model of its physical store design. The site should be live in two weeks.
"This market is exploding with potential right now," continued Mr. Lovatt. "Growth estimates for the CBD market continue to ratchet higher. That matches what we are seeing from a boots-on-the-ground perspective as well. We have a very disruptive vision and we want to mobilize it as fast as possible. But the details need to be addressed with proper care. To that end, the Oxygen team brings professionalism, talent, and a wealth of experience to the table."
Recent Developments for GTEH:
GenTech Announces Official Launch in $2B CBD Market with First US Location
Yesterday, GTEH announced the establishment of final lease negotiations for its first CBD coffee shop location, with a five-year lease now under review. The negotiation comes as part of an aggressive multi-week process during which the Company expects to confirm the towns chosen for its first three locations.
“We have been all over the East Coast during the past couple weeks, working to nail down our initial locations,” noted David Lovatt, CEO of GenTech. “We first went to Miami, FL, in the trendy Wynwood area, then to Montclair, NJ, a wealthy suburban haven for professionals from New Jersey and New York. From there, we headed to SOHO and Williamsburg in New York – both extremely trendy, high-volume locations. The process has been highly productive, and we should have firm contractual commitments in place very soon, which will set in motion the most exciting steps of this strategy.”
Management notes that the Company is now in a position to begin work on securing at least one location over the very near term, with several others likely to follow.
The GenTech media team was also a part of the process, and the Company plans to release footage in the form of “video blogs” of the Company’s likely store locations to give shareholders a clear sense of the process in motion and the rare quality of the locations being considered as initial Healthy Leaf CBD Coffee Shop sites.
“The Healthy Leaf pivot is moving at an extremely fast clip at this point,” continued Mr. Lovatt. “We are on the verge of nailing down our initial locations imminently, we expect to unveil our initial branding designs within the next week, the new website will be completed and unveiled within the next two weeks, and all of this will be transparently accessible to shareholders and the wider investment audience in real time as it unfolds.”
Market Outlook
According to "www.votehemp.com," the 2017 market for Hemp was buoyant with 13% of the $820m US market being made up of Consumer textiles, CBD making up 23% of that market and Food being 17%. They project that CBD oil derived products will exceed $646 million alone by 2022.
The CBD market is one of the fastest growing consumer product markets on the planet right now, with some analysts projecting as much as 20x growth over the next 36 months. One of the truly unique facets to this growth curve is that has not been sponsored by any major existing brands from established large-cap corporate entities. It has been truly organic.
Technical Analysis
As we mentioned above, we may have never had an alert with a float this tight.
Yahoo Finance has the float on GTEH listed at just 1.12M.
We did the quick math, and that equates to just slight above $32K worth of shares available to the public for trading!
With a float that tight, it's no wonder why GTEH has a proven history of monster single day moves.
Here is just a small taste of the type of single-session gains GTEH is capable of delivering:
5/24 $0.0205 to $0.0339 for a gain of +65.37%
5/20 $0.0321 to $0.0440 for a gain of +37.07%
5/15 $$0.0340 to $0.0675 for a gain of +98.53%
4/30 $0.015 to $0.0270 for a gain of +80%
We've done our very own chart analysis and see the potential for a move of over +282%!
The Bottom Line
If you are on the hunt for monster single-session gains, then GTEH is the only ticker that should be on your radar.
That being said, we ask that you start your research on GTEH immediately and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for GTEH. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Unsubscribe
This message was sent to jay.stockrockandroll@gmail.com from info@topmarketgainers.com
Top Market Gainers
MJ Capital, LLC | PennyStockLocks, LLC
PO Box 110226
Nutley, NJ 07110
TESLA INC. Top opportunity to join ? Hello,
How do u think about my TSLA trade plan ?
Market Status : Oversold
Buy : 180-185
SL : 174
TP : 235+ (trail stop)
A Bullish corrective wave is about to take place!After the bearish opportunity confirmed due to the intersection of Tenkan-Sen with Kijun-Sen which heading the price downward under Ichimoku cloud at 109.471 , while the Stochastic index recording an overselling which is predictable a profits gain can occur in form of a bullish corrective wave.
BULLISH Divergence on RSI - Falling Wedge - Potential BUYNZDJPY is breaking out from a falling wedge.
The RSI is signalling a bullish divergence
BUY up to the first target of 73.00
Oscilator RSI- Crypto Low price on point A, elevated volume, is confirmed by reviewing stochastic RSI where we can see stock is over sold, and this will create variation on pattern and add volatility .
Same case works for point B, with a higher variation on price, and lower volume, but volatility is created, and stock is oversold.
Point C, has a price increase, which confirms volatility, and stock is over bought.
PARTY LIKE ITS 1999"Those Who Do Not Learn History Are Doomed To Repeat It."
Qualcomm is mimicking the Chart Pattern it took during 1999-2000. QCOM just spiked over 45%, similar to the meteoric rise it experienced during the Dotcom bubble. The correction that Qualcomm is experiencing will reverse quickly after Chinese impose their retaliatory tariffs. (June 1st) So Before July 19th we should see another pulse upward in-between 5-15% that replicates the spike in 2000 after the initial price action. MACD, RSI, volatility and time cycles all play key factors here. After the pulse whether QCOM rises or falls depends on the trend of AAPL and the market.
$TNXP looks ready to breakout big today. This low-float Nasdaq..TNXP looks ready to breakout big today. This low-float Nasdaq listed company could cure PSTD!
========================
TNXP (Tonix Pharmaceuticals Holding Corp.)
Alert Price: $1.70
Float: 4.74M
Chart Analysis
Roth Capital Price Target: $4.00
Investor Presentation
Company Website | Recent News
========================
Members,
We ask that you give your full attention to our new low-float Nasdaq listed alert TNXP (Tonix Pharmaceuticals Holding Corp.).
TNXP is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD.
PTSD is a serious chronic psychiatric illness defined as a maladaptive prolonged stress response which occurs after experiencing severely injurious traumatic event(s). While initially recognized as a stress response to military combat ('shell shock') it is now known that many civilians exposed to life-threatening events, sexual assault, natural disasters or accidents, can develop PTSD.
According to the latest report published by Credence Research, Inc. the global post-traumatic stress disorder therapeutics market is projected to reach US $10.679M by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.
TNXP Has the Potential to Be the Biggest Gainer On the Nasdaq
With its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
Take a look at these past single-session gains:
3/14 $2.58 to $3.24 for gains of +25.58%
3/11 $2.80 to $4.12 for gains of +47.14%
3/8 $2.14 to $4.20 for gains of +96.26%
12/7 $3.15 to $7.24 for gains of +129.84%
TNXP also has several bullish catalysts on the horizon:
Chart has recently formed a "Golden Cross" which generally signals an uptrend.
Roth Capital analyst Scott Henry upgraded TNXP from Neutral to Buy with a price target of $4.00.
The Company will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting.
Research has shown that PSTD treatment is not just for soldiers: Civilians with PTSD struggle to find effective therapy
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for fibromyalgia and agitation in Alzheimer’s disease under separate INDs to support potential pivotal efficacy studies. The fibromyalgia program is in Phase 3 development and the agitation in Alzheimer’s program is Phase 2 ready. The agitation in Alzheimer’s disease IND has been designated a Fast Track development program by the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a different mechanism from TNX-102 SL and designed for daytime dosing. TNX-601 is also in development for a potential indication - neurocognitive dysfunction associated with corticosteroid use. A Phase 1 clinical formulation selection pharmacokinetic study of TNX-601 will be conducted outside of the U.S. in 2019. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
* TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
**Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL for the treatment of PTSD.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Company Highlights:
Phase 3 development of new bedtime treatment for PTSD, including military related PTSD
Major unmet need; ~12 million Americans annually
Benefited from FDA 505(b)(2) NDA approval requirement
Complimentary day-time PTSD treatment in development
Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution
Fibromyalgia bedtime treatment in development
New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication
New indication in development for agitation in Alzheimer’s Disease
Unmet medical need, no approved drug available
Fast Track Phase 2/3 ready program
Innovative vaccine in development to prevent Smallpox
Opportunity to supply stockpiling requirement; short development path
Studies in mice suggest improved safety profile
Recently Completed Milestones
July 2018 Completed P301/HONOR study interim analysis - result did not support study continuation but strengthened new Phase 3 study
August 2018 Presentation of P301/HONOR study results at Military Health System Scientific Symposium
October 2018 Met with FDA and received preliminary agreement on the design of new Phase 3 study of Tonmya for PTSD (P302/RECOVERY study)
November 2018 Received FDA minutes confirming agreement on the design of P302/RECOVERY study
March 2019 Met with FDA to discuss new FM Phase 3 study design using TNX-102 SL 5.6 mg
March 2019 P302/RECOVERY study initiated
April 2019 Received FDA formal minutes with clear guidance and support on new Phase 3 FM study
Upcoming Milestones
Second Half 2019 Preliminary human pharmacokinetic and safety data (non-IND study) from selected TNX-601 (tianeptine oxalate) formulation expected
First Half 2020 Topline data from P302/RECOVERY study expected
Market Outlook
Globally, the vast majority of people (~70%) will experience or witness one or more life-threatening traumatic events in their life-time. For many, the response to an isolated traumatic event will dissipate over days or a few weeks and have little or no long-term consequences.
For some individuals, however, the response to trauma will become chronic, lasting for more than one month and persisting for years, and, in many cases, decades. These individuals are considered to have PTSD and will experience psychiatric symptoms (flashbacks, intense anxiety and avoidance, emotional numbness, intense guilt or worry, agitation, sleep disturbances), and as a consequence, experience impaired social functioning, occupational disability, and an overall poor quality of life. PTSD is also characterized by overall high utilization of healthcare services, adding to the significant economic burden from the condition.
How prevalent is PTSD?
PTSD is a global problem, with the lifetime prevalence of PTSD estimated to be 3.9%, or affecting an estimated 200-300 million individuals, on a global basis.
Based on U.S. 12-month prevalence rates,1,2 it is estimated that about 11.0 million American adults suffer from DSM-5-defined PTSD in a given year. Similar to other psychiatric disorders, only approximately half of these individuals will seek treatment at some point in the course of the disease, and of these, approximately 40% (~1.8 million) will be formally diagnosed with PTSD in any given year. Lack of awareness, the negative stigma associated with PTSD (like other mental disorders), as well as the limitations of existing treatment options, may be addressed by increased societal awareness and acceptance as well as the introduction of new therapeutic options.
Technical Analysis
As we stated above, with its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
TNXP's chart has recently formed a "Golden Cross" which generally signals an uptrend.
We've done our very own chart analysis, and see the potential for a move of over +27%!
The Bottom Line
We are extremely bullish on TNXP.
Based on our research we believe that this could be the biggest single-day gainer on the Nasdaq today.
That being said, we ask that you start your research on TNXP immediately and consider building a position this morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have NOTbeen compensated to conduct investor relations advertising and marketing for TNXP. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
